DR. HEMANT SREENIVASA MURTHY M.D. NPI 1518129188

NPI Details

DR. Hemant Sreenivasa Murthy, M.D. is a hematology and oncology internal medicine in Jacksonville, FL with 18 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Hemant Sreenivasa Murthy, M.D. NPI is 1518129188. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

4500 SAN PABLO RD S
JACKSONVILLE, FL
ZIP 32224-865
Phone: (904) 953-2000

The NPI 1518129188 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, durvalumab, 10 mg (HCPCS:J9173)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Collection of blood sample from implanted device (HCPCS:36591)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection of drug or substance into vein (HCPCS:96374)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Hospital discharge day management, more than 30 minutes (HCPCS:99239)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)

The enumeration date for this NPI number is 6/25/2008 and was last updated on 9/2/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.